Innovation1 Biotech Inc
Innovation1 Biotech Inc. focuses on researching, developing, producing, and selling pharmaceutical products. The company offers natural supplements for the treatment of symptoms associated with the flu and long covid under the NutraFlu and Nutravid19 brands; and other supplement and medical nutrition products. It also develops NLC001 that is in Phase II clinical trial for the treatment of long co… Read more
Innovation1 Biotech Inc (IVBT) - Net Assets
Latest net assets as of February 2024: $-3.34 Million USD
Based on the latest financial reports, Innovation1 Biotech Inc (IVBT) has net assets worth $-3.34 Million USD as of February 2024.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($121.50K) and total liabilities ($3.46 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $-3.34 Million |
| % of Total Assets | -2746.71% |
| Annual Growth Rate | N/A |
| 5-Year Change | -10699.06% |
| 10-Year Change | N/A |
| Growth Volatility | 3877.48 |
Innovation1 Biotech Inc - Net Assets Trend (2018–2023)
This chart illustrates how Innovation1 Biotech Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Innovation1 Biotech Inc (2018–2023)
The table below shows the annual net assets of Innovation1 Biotech Inc from 2018 to 2023.
| Year | Net Assets | Change |
|---|---|---|
| 2023-08-31 | $-3.43 Million | -220.24% |
| 2022-08-31 | $2.85 Million | +1368.72% |
| 2021-08-31 | $-224.84K | +91.60% |
| 2020-08-31 | $-2.68 Million | -8375.41% |
| 2019-08-31 | $32.36K | -81.60% |
| 2018-08-31 | $175.88K | -- |
Equity Component Analysis
This analysis shows how different components contribute to Innovation1 Biotech Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 5763724600.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (August 2023)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | $55.20 Million | % |
| Total Equity | $-3.43 Million | 100.00% |
Innovation1 Biotech Inc Competitors by Market Cap
The table below lists competitors of Innovation1 Biotech Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Hempacco Co., Inc.
PINK:HPCO
|
$4.49K |
|
INNODIS LTD
SEM:HWF
|
$4.50K |
|
Aartech Solonics Limited
NSE:AARTECH
|
$4.50K |
|
Lecico Egypt
EGX:LCSW
|
$4.50K |
|
Optima Medical Innovations Corp
PINK:TOKIF
|
$4.49K |
|
Evolution Global Acquisition Corp Warrants
NASDAQ:EVOXW
|
$4.48K |
|
TJIWI KIMIA
MU:OB9
|
$4.48K |
|
PT Merdeka Gold Resources Tbk
JK:EMAS
|
$4.48K |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Innovation1 Biotech Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2022 to 2023, total equity changed from 2,852,573 to -3,429,963, a change of -6,282,536 (-220.2%).
- Net loss of 5,988,266 reduced equity.
- Other factors decreased equity by 294,270.
Equity Change Factors (2022 to 2023)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-5.99 Million | -174.59% |
| Other Changes | $-294.27K | -8.58% |
| Total Change | $- | -220.24% |
Book Value vs Market Value Analysis
This analysis compares Innovation1 Biotech Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2018-08-31 | $0.41 | $0.00 | x |
| 2019-08-31 | $0.07 | $0.00 | x |
| 2020-08-31 | $-14.31 | $0.00 | x |
| 2021-08-31 | $-1.19 | $0.00 | x |
| 2022-08-31 | $0.14 | $0.00 | x |
| 2023-08-31 | $-0.17 | $0.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Innovation1 Biotech Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is above the historical average (-418.87%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2018 | -554.67% | -5816.73% | 0.02x | 4.91x | $-993.11K |
| 2019 | -525.53% | -214.61% | 0.31x | 7.92x | $-173.30K |
| 2020 | 0.00% | -218464.69% | 0.01x | 0.00x | $-2.31 Million |
| 2021 | 0.00% | 33764.03% | 0.02x | 0.00x | $1.06 Million |
| 2022 | -1433.02% | 0.00% | 0.00x | 15.41x | $-41.16 Million |
| 2023 | 0.00% | 0.00% | 0.00x | 0.00x | $-5.65 Million |
Industry Comparison
This section compares Innovation1 Biotech Inc's net assets metrics with peer companies in the Shell Companies industry.
Industry Context
- Industry: Shell Companies
- Average net assets among peers: $36,677,338
- Average return on equity (ROE) among peers: -64.57%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Innovation1 Biotech Inc (IVBT) | $-3.34 Million | -554.67% | N/A | $4.49K |
| Artius II Acquisition Inc. Class A Ordinary Shares (AACB) | $-60.27K | 0.00% | 0.00x | $198.37 Million |
| Artius II Acquisition Inc. Units (AACBU) | $-60.27K | 0.00% | 0.00x | $205.28 Million |
| Ares Acquisition Corporation II (AACT-UN) | $931.34 Million | 0.00% | 0.08x | $399.77 Million |
| AA Mission Acquisition Corp. (AAM-UN) | $-559.90 Million | 0.00% | 0.00x | $349.76 Million |
| Global Acquisitions Corporation (AASP) | $3.80 Million | -5.26% | 0.34x | $15.42 Million |
| ABV Consulting Inc (ABVN) | $8.75K | -623.31% | 2.50x | $461.96K |
| Atlantic Coastal Acquisition Corp II (ACAB) | $-8.52 Million | 0.00% | 0.00x | $2.44 Million |
| Annabidiol Corp (ACBD) | $-501.57K | 0.00% | 0.00x | $13.62K |
| ACRO Biomedical Co Ltd (ACBM) | $685.87K | -17.12% | 0.46x | $30.04K |
| Huaizhong Health Group Inc (ADAD) | $-19.47K | 0.00% | 0.00x | $3.15K |